1. Home
  2. RYOJ vs MURA Comparison

RYOJ vs MURA Comparison

Compare RYOJ & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RYOJ

rYojbaba Co. Ltd. Common Shares

N/A

Current Price

$4.03

Market Cap

42.8M

ML Signal

N/A

Logo Mural Oncology plc

MURA

Mural Oncology plc

HOLD

Current Price

$2.04

Market Cap

36.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYOJ
MURA
Founded
2015
2013
Country
Japan
Ireland
Employees
N/A
N/A
Industry
Professional Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
42.8M
36.0M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
RYOJ
MURA
Price
$4.03
$2.04
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
71.7K
224.8K
Earning Date
12-19-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
72.91
N/A
EPS
0.13
N/A
Revenue
$11,576,848.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$30.25
N/A
Revenue Growth
5.60
N/A
52 Week Low
$1.81
$0.95
52 Week High
$11.43
$4.74

Technical Indicators

Market Signals
Indicator
RYOJ
MURA
Relative Strength Index (RSI) N/A 40.39
Support Level N/A $2.06
Resistance Level N/A $2.10
Average True Range (ATR) 0.00 0.01
MACD 0.00 -0.01
Stochastic Oscillator 0.00 25.00

Price Performance

Historical Comparison
RYOJ
MURA

About RYOJ rYojbaba Co. Ltd. Common Shares

rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Share on Social Networks: